Good news for two accelerators


F10 Zurich has a new Head. And Baselaunch has a new partner. It’s the first VC supporting the Basel Area-based biotech venture accelerator and incubator.


F10 has appointed Gerrit Sindermann as new Head F10 Zurich. Gerrit will join F10 FinTech Incubator & Accelerator mid of June 2020 to lead the mission of guiding start-ups in transforming their ideas into successful companies while stimulating worldwide collaboration with international finance organizations. In his role, he will be responsible for the overall development of F10 Zurich, its programs as well as the service portfolio. Moreover, he will manage the relationship with F10’s Corporate Members and related business development, including fundraising, to support the team’s continued successful growth and evolution of F10. F10 – THE HOME OF FINTECH describes itself as an ecosystem of start-ups, corporates, experts and Investors reshaping global finance through talent, technology and dedication.

Gerrit Sindermann has experience in international corporations (Swisscom, ABN AMRO Bank) and entrepreneurial ventures (Contovista, milliPay, Nexmo). Additionally, he is highly skilled in business development, strategy and identifying, building and managing partnerships. On top, he has in-depth industry knowledge in banking and FinTech. F10 co-founder and board member Andreas Iten says, “I am very pleased to share the news. We are delighted to have Gerrit on board, and we are convinced that with his diverse background and entrepreneurial drive, he will complement the existing team ideally and help to take F10 to the next level.”

BB Pureos Bioventures joins BaseLaunch Phase II

Pureos joins Roche in supporting BaseLaunch’s investment in innovation, with additional partners being announced over the coming weeks and months. Building on the success of its first phase, BaseLaunch Phase II will:

  • Increase funding per venture to a maximum of USD 0.5 million (versus USD 0.25 million previously)
  • Have a new, and increased pool of partners
  • Establish BaseLaunch as an “evergreen” permanent initiative
  • Accept applications year-round, rather than once per year 

Pureos is a newly formed venture capital fund located in Zurich to exclusively invest in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. Pureos is advised by Bellevue Asset Management, which manages more than USD 11 billion and has been active in the healthcare investing since 1993. Anja Harmeier, Partner at BB Pureos Bioventures commented: “We are delighted to join BaseLaunch as a partner in the next phase of its company building activities. The Pureos team worked closely with BaseLaunch during the Series A funding of Alentis Therapeutics and has been very impressed by the team and the quality of the selected programs. As the sole Swiss venture capital fund to join, we look forward to developing our partnership further to support and invest in the next generation of innovative drug development companies in Switzerland and beyond.”

Stephan Emmerth, Director Business Development & Operations at BaseLaunch, added: “We are very pleased to welcome Pureos as a partner in BaseLaunch Phase II. As a venture fund, Pureos brings not only operational experience and financing, but also the entrepreneurial flair needed to support and develop early stage therapeutic science. Against an uncertain outlook for many startups due to COVID-19, BaseLaunch is ideally positioned to help launch the next generation of cutting-edge therapeutic ventures, with the partnership of proven companies in place to fund and develop projects exhibiting transformational science.”

BaseLaunch serves as an accelerator and incubator for early stage ventures developing cutting-edge therapeutics. BaseLaunch helps build companies from inception through to Series A funding, providing financing and supporting all aspects of business development. BaseLaunch Phase II is now open for applications (first application deadline 22 June 2020).

(Press release / SK)